Supplementary downloadable tables

The tables deal with prevalence of infectious diseases (specifically, HIV, HCV and HBV) among injecting drug users and with new notifications of these diseases among drug users, as well as to a description of the methods and definitions used in compiling this data. Summary tables by country show estimates of the percentage of IDUs infected. Fuller tables on which the summaries are based can be found in the statistical bulletin annex.

Table INF-4. HIV infections newly diagnosed in injecting drug users, by year of report from 1992 to 2003, (a) cases per million population and (b) number of cases

Table INF-5. Notified cases of hepatitis C infection among injecting drug users: number of IDUs and percentage of IDUs among all cases with known risk factor

Table INF-5 part (i). Notifications IDUs with hepatitis C
Table INF-5 part (ii). Notes and comments

Table INF-6. Notified cases of hepatitis B infection among injecting drug users: number of IDUs and percentage of IDUs among all cases with known risk factor

Table INF-6 part (i). Notifications of IDUs with hepatitis B
Table INF-6 part (ii). Notes and comments

Table INF-7. Incidence of hepatitis C virus antibody among injecting drug users

Table INF-8. Prevalence of HIV infection (%) among injecting drug users in the EU

Table INF-8 part (i). Data
Table INF-8 part (ii). Notes

Table INF-9. Prevalence of HIV infection (%) among injecting drug users under age 25, in the EU

Table INF-9 part (i). Data
Table INF-9 part (ii). Notes

Table INF-10. Prevalence of HIV infection (%) among new injecting drug users (injecting less than 2 years) in the EU

Table INF-10 part (i). Data
Table INF-10 part (ii). Notes

Table INF-11. Prevalence of hepatitis C infection (%) among injecting drug users in the EU

Table INF-11 part (i). Data
Table INF-11 part (ii). Notes

Table INF-12. Prevalence of hepatitis C infection (%) among injecting drug users under age 25 in the EU

Table INF-12 part (i). Data
Table INF-12 part (ii). Notes

Table INF-13. Prevalence of hepatitis C infection (%) among new injecting drug users (injecting less than 2 years) in the EU

Table INF-13 part (i). Data
Table INF-13 part (ii). Notes

Table INF-14. Prevalence of current hepatitis B infection (% with HBsAg) among injecting drug users in the EU

Table INF-14 part (i). Data
Table INF-14 part (ii). Notes

Table INF-15. Prevalence of antibodies against hepatitis B virus (%) among injecting drug users in the EU

Table INF-15 part (i). Data
Table INF-15 part (ii). Notes